Performance: The future of cell therapy is to be xenogeneic-free and therefore human platelet lysate offers xenogeneic free/serum substitutes for replacing FBS and improving cell culture performance.
Cost: FBS is commonly used at concentration between 10-20% in cell culture. However due to the high performance effects of human platelet lysate, it is typically used at lower concentrations; 2.5%, 5% or 10%.
Batch-to-batch variation: Batch-to-batch variability of hPL is significantly lower than that of FBS since it is derived from standardized human blood products. Since hPL is obtained from multiple donors units that are subsequently pooled in large batch sizes, it enables the manufacture of a consistent product with minimal lot-to-lot variation.